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INTRODUCTION
Eczema is a common condition in children, 
characterised by dry skin and intermittent 
flares. In the UK, the majority of children with 
eczema can be effectively treated in primary 
care with topical treatments: emollients 
and topical corticosteroids (TCS).1 However, 
regimes to moisturise the skin and manage 
flares can be complex and challenging for 
parents in terms of knowing when and how 
to apply treatments, as well as managing 
other factors that can exacerbate eczema.2 
Failure to use topical treatments correctly 
is common3 and is the main cause of poor 
clinical outcomes,1,4–6 with negative effects on 
the quality of life of the child and their family.7,8 
Research with patients and carers has 
identified barriers to effective treatment, 
including lack of understanding about the 
condition and treatments,8,9 and reluctance 
to use TCS because of concerns about 
side effects.4,10 Written action plans (WAPs) 
are patient- or carer-held instructions to 
support self-management. They have the 
potential to address these problems and 
improve outcomes for affected children and 
their families,8 and their use is advocated by 
national guidelines.1,11
WAPs have been shown to improve 
clinical outcomes in asthma,12–14 which is 
also common in children and requires a 
high degree of self-management. However, 
research into self-management of eczema 
has only identified two trials of WAPs, 
both of limited methodological quality.15 
Furthermore, eczema WAPs have not been 
subject to prior developmental work with 
respect to acceptability, structure, or content. 
The aims of this study were to work 
with health professionals, patients, and 
stakeholders to explore the perceived value 
of an eczema WAP, and to develop a WAP 
that could be used to support eczema self-
management in primary care. 
METHOD
The authors undertook 41 semi-structured 
interviews and two focus groups with 
parents of children with eczema, GPs, and 
a range of other clinicians and stakeholders 
between May 2016 and February 2017. They 
focused on children under 12 years with 
mild to moderate eczema because these 
represent the majority of eczema cases 
in primary care, and because the needs 
of adolescents and adults are likely to be 
different.1 
Sampling and recruitment
The authors identified five socioeconomically 
diverse practices in and around Bristol, 
UK. Each practice searched its electronic 
medical records and sent an invitation 
letter to around 100 randomly selected 
parents of children aged <12 years who 
had an eczema diagnosis. Primary care 
healthcare professionals (GPs, practice 
nurses, and health visitors) were recruited 
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at participating practices and via personal 
and professional networks. 
Parents and healthcare professionals 
expressed interest in taking part in interviews 
and/or focus groups by completing an online 
or paper questionnaire, and their responses 
were used for purposive sampling. Parents 
were sampled by socioeconomic status 
(calculated from their home postcode), age, 
sex, ethnicity of their child with eczema, 
and self-rated eczema severity (POEM: 
patient-oriented eczema measure).16 Older 
children, at the discretion of the parent, 
were also invited to take part in the interview. 
GPs were sampled by sex, years in job role, 
sociodemographic area of practice, and 
experience of using, and their perceived 
value of, WAPs. 
Other stakeholders included secondary 
care clinicians (dermatologists, dermatology 
nurses, and allergy consultants), who 
were identified by snowballing and 
professional networks, and eczema charity 
representatives, school nurses, and nursery 
staff, who were identified via eczema 
charities and local school networks. 
Interviews. In-depth interviews enabled the 
authors to collect data on the individual 
experiences and challenges of managing 
and treating eczema from the perspective 
of carers and healthcare professionals, as 
well as the elements that participants would 
find helpful in a WAP. They also provided the 
opportunity for participants to give feedback 
on the initial drafts of the WAP, which the 
authors developed and refined iteratively 
alongside the interviews. The interviews 
were held in participants’ homes, on NHS 
premises, or by telephone, and lasted 
45–60 minutes. A semi-structured topic 
guide was developed for each participant 
group (that is, parents, clinicians, and 
stakeholders) and piloted (Box 1). Topics 
were modified over the course of the data 
collection in response to emergent topics 
of interest. 
One of the authors, a GP with a specialist 
interest in dermatology, conducted 
the majority (13/15) of GP interviews. 
Another author, a non-clinical researcher, 
interviewed other participants. To facilitate 
discussion, early interviewees were shown 
three example WAPs, which varied in 
length, layout, and graphical content. Two 
were eczema-specific WAPs, one developed 
by the Hillingdon Hospitals NHS Foundation 
Trust, and the other by the Australasian 
Society of Clinical Immunology and Allergy 
(ASCIA). The third was a WAP for patients 
with asthma developed by Asthma UK. 
Sample WAPs were replaced in later 
interviews with successive drafts of the 
study WAP.
Focus groups
Focus groups were employed to further 
refine, and reach a consensus around, the 
draft study WAPs. The first group was held 
towards the end of data collection, when the 
majority of the individual interviews (n = 35) 
had been conducted, and the second group 
was the final part of data collection, when 
data saturation from one-to-one interviews 
had been reached. Representatives 
were recruited from across the different 
participant groups to each focus group to 
promote a balanced discussion. For the 
first focus group discussion (FGD1), the 
authors invited primary care healthcare 
professionals (GPs, pharmacists, and 
eczema charity representatives) and 
parents who had been interviewed, because 
they understood the research aims and lived 
locally enough to travel to the university 
premises where the groups were held. For 
the second focus group discussion (FGD2), 
all those who had taken part in the first 
focus group were asked again, with the 
invitation being extended to a further four 
GPs, nine parents, and local secondary 
care healthcare professionals who had 
expressed interest in taking part, or who 
had already participated in an interview.
Each focus group lasted 1.5 hours. One of 
the authors, an academic GP with a research 
interest in eczema, led the discussion, 
ensuring all views were heard. Another 
observed and took notes. A separate topic 
guide was used for each group (Box 1). 
Transcription and end of data collection. 
Groups and interviews were audiorecorded, 
transcribed verbatim, and anonymised. 
How this fits in
Incorrect use of topical treatments is 
common in children with eczema, and 
contributes to poor clinical outcomes. 
Written action plans (WAPs), drawn up 
between healthcare professionals and 
parents and children, could support the 
self-management of eczema. The parents, 
GPs, and other healthcare professionals 
in this study felt that a WAP could improve 
parents’ knowledge and confidence in 
using and applying prescribed treatments. 
Using interviews and focus groups, the 
authors developed an eczema WAP, 
comprising individualised treatment 
guidance, generic eczema information, and 
a treatment log. 
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Data collection ended at the point of data 
saturation, when new insights related to 
the research questions ceased to emerge.17
Data analysis
Transcripts were imported into QSR NVivo 
(version 10). Data were analysed thematically.18 
Two authors used the broad requirements 
of the WAP to deductively develop codes, 
but were also open to inductively identifying 
codes and themes that could enhance the 
acceptability of the developing WAP. To 
maximise rigour, eight interview transcripts 
were coded by two authors independently and 
then compared to assess coding agreement, 
resolve any discrepancies, and identify new 
emergent codes. One author then coded the 
remaining transcripts for the primary care 
healthcare professionals, and the other coded 
the remainder of the parent, stakeholder, 
and secondary care healthcare professional 
transcripts. The same codes were applied 
to the interviews and focus groups. Codes 
within and between participant groups were 
compared and grouped into themes and 
sub-themes. 
The authors developed and refined 
an eczema WAP over the course of the 
study. The final draft was produced with 
the assistance of a professional graphic 
designer, to maximise its visual appeal and 
usability. 
Ethics
All participants were given written 
information about the study, and written 
informed consent (or assent for children) 
was received prior to the interview or focus 
group. All participants were nominally 
reimbursed for their time. 
RESULTS
Participant recruitment and 
characteristics
Figure 1 shows the recruitment process 
for parents and healthcare professionals 
(n = 37). The four other stakeholders 
were self-selected from the organisations 
approached. Table 1 describes interview and/
or focus group participants. In all, 13 parents, 
two children, 24 primary care healthcare 
professionals, six secondary care healthcare 
Parents
511 letters sent out from five practices
53 parents expressed interest
19 parents invited to interview,
plus one parent from PPI network,
nine invited to FGD1, 16 invited to
FGD2
11 took
part in
interview
One took
part in
FGD1
Three took
part in
FGD2
Primary care professionals
Five practices sent
invitation e-mail to
GPs, practice nurses,
and health visitors
Other GPs were
invited via personal
and professional
networks
48 GPs, one pharmacist, 10 practice nurses,
and seven health visitors expressed interest
32 GPs, one pharmacist, seven practice nurses,
and four health visitors were invited to interview;
18 GPs, two health visitors, one pharmacist, and
one practice nurse invited to FGD1; seven GPs,
two health visitors, one pharmacist, and
two practice nurses invited to FGD2
15 GPs, one
pharmacist, two
practice nurses,
and three health
visitors took
part in an
interview
Three GPs and
one pharmacist
took part in
FGD1
Two GPs and
one pharmacist
took part in
FGD2
Secondary care professionals
One
dermatology
nurse
took part in
FGD2
Dermatology specialists invited via
professional networks
13 dermatologists, one allergy consultant, and
16 dermatology nurses expressed interest
One dermatologist, one allergy consultant, and
three dermatology nurses were invited to interview
One
dermatologist,
one allergy
consultant, and
three
dermatology
nurses took
part in an
interview
No secondary
care
practitioners
took part in
FGD1
Figure 1. Flowchart of recruitment pathway for 
parents and healthcare professionals. FGD1 = focus 
group discussion 1. FGD2 = focus group discussion 2. 
PPI = patient and public involvement.
Box 1. Topic guide framework 
Interviews Focus groups
• Experience of managing eczema • Thoughts on findings to date
• Barriers and facilitators to eczema self-management • Critique of draft WAP
• Previous use of WAPs • Factors to consider for implementation of WAP
• Perceived value of WAPs
• Content and design preferences of the WAP
• Critique of example or draft WAPs
• Completing, sharing, and updating WAPs
• Training and/or resources needed to support use of WAPs
WAP = written action plan.
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professionals, and four stakeholders took 
part. Participating parents’ children ranged 
from 0–11 years, with POEMs between 1–24 
(that is, clear/mild to severe eczema),19 and 
varied ethnicity (three black, one mixed race, 
nine white). The authors identified three 
main themes: the challenges of managing 
eczema, eczema WAP acceptability, format, 
and content, and finalising the WAP. 
The challenges of managing eczema
Lack of support and information. Parents 
voiced frustrations at feeling unsupported 
by GPs in terms of treatment, and felt 
their information needs were not met. The 
absence of specific verbal advice on how to 
apply emollients and TCS in terms of when, 
where, how often, and how much was either 
absent or unclear, leading to uncertainty 
with treatment application: 
‘It was just, stick it on his legs. It really was 
just a kind of “here you go, this is it, and off 
you go”.’ (Parent [P]10)
GPs reported not providing written 
information to patients with eczema 
regularly. If they did, it was usually a generic 
leaflet printed from their clinical system or 
website. When individualised guidance was 
given, it tended to be in an ad hoc manner:
‘No, I don’t tend to give written information 
unless I think, “OK, this person really doesn’t 
know much about what they’re doing,” In 
which case, I might print out the patient 
information leaflet from Patient UK.’ (GP4)
Views about causes and management. 
Several parents held views about the 
causes and best method of treatment for 
eczema that differed from the approach 
expressed by healthcare professionals. 
Some parents believed eczema had a root 
cause, such as an allergy, which needed 
to be identified and avoided, rather than 
it being an inherent condition that needs 
to be managed with emollients and TCS. 
GPs recognised this issue, which they said 
got in the way of successfully treating and 
managing the condition:
‘I think they expect that, if they can find the 
one trigger for the eczema, they can make it 
all magically go away, so you have to unpick 
that.’ (GP14)
‘They’re going to give me the same thing 
they’ve been giving me for about a year, so 
it doesn’t really make any sense if there’s 
nothing to cure my daughter of the eczema.’ 
(P9)
Documenting treatment preferences. Many 
parents and healthcare professionals 
agreed that treatment tended to be on a 
trial-and-error basis. However, finding a 
treatment regime that works for the family is 
difficult because parents reported difficulty 
in remembering names of treatments tried. 
Also, the reasons for stopping a treatment 
are not routinely recorded by GPs, meaning 
failed treatments may be re-issued: 
‘It’s [name of treatment] in the notes, but 
what you get is, it’s unclear whether the 
treatments worked and they stopped using 
them, or it hasn’t been effective and they’ve 
never used it again.’ (GP16, FGD1) 
Eczema WAP acceptability, format, and 
content
Box 2 gives an overview of what participants 
wanted from a WAP. However, differing 
opinions on its format and content were 
commonplace.
Benefits of a WAP. Participants were 
generally positive about the role that 
WAPs could play in addressing barriers to 
eczema management. Potential benefits 
identified included a documented treatment 
plan, patients and carers empowered and 
confident to use treatments, an eczema 
information resource, and improved clinical 
outcomes. 
Individualised action steps. Participants 
wanted a treatment plan that was 
individualised and specific. Also, plans 
Table 1. Participant characteristicsa
  Focus group participants
Participant group Interview participants Focus group 1  Focus group 2 
Parent 11 1 (1) 3 (1) [1]
GP 14 3 (1) 2 (2) [1]
GPwSI 1 0 0
Practice nurse 2 0 0
Health visitor 3 0 0
Pharmacist 1 1 (1) 1 (1) [1]
Dermatology nurse 3 0  1 (1)
Dermatology consultant 1 0 0
Allergy consultant 1 0 0
School nurse 1 0 0
Nursery manager 1 0 0
Eczema charity representative 2 0 0
Total	 41	 5	 7
a(round brackets denote the number who also took part in an interview), [square brackets and in bold denote 
number who also took part in focus group]. GPwSI = GP with a special interest. 
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should be presented in a stepped approach, 
that is: step 1, what to do when the condition 
is stable; step 2, what to do when there 
is a flare; and ‘how to get between the 
two’ steps (paediatric allergy consultant). 
Early interviewees who were shown the 
Hillingdon and Asthma UK example WAPs 
that take this approach thought they were a 
good model to follow: 
‘I really liked that they had four, you know, 
they had sections on when the skin was 
kind of manageable, and what to do just to 
kind of maintain the skin, and then when 
there was actually a flare.’ (Eczema charity 
representative 2)
All groups wanted an additional third 
step indicating action to take if the condition 
does not respond to advised treatment: 
‘There’s not a lot of support from doctors, 
and it’s hard to know when to take him back. 
I don’t want to be like a fussy parent, “oh, 
they’re back again with a bit of eczema”, but 
like I said, you know, it’s his skin.’ (P3)
Participants agreed that the WAP 
should be specific about what to use and 
when, including volume, frequency, and 
duration. It was also suggested that web 
links to videos demonstrating how to apply 
treatments be added. 
Some also felt that providing space 
for a treatment log to document parents’ 
experiences would help either prevent 
re-prescribing of failed treatments, or 
facilitate re-ordering a successful treatment: 
‘If I ring up the doctors and say “can I get 
another, you know, that one”, I couldn’t 
remember the name of it, so I was like 
“hang on, I’ve got to find the thing”, and 
have to go and rummage. So, yeah, if I had 
it all on there, I’d probably keep that on 
my fridge or something, and it’d just be all 
there then, in front of me.’ (P3)
‘What I like, from my perspective as a GP, 
is the log of previous treatments tried. It’s 
really common that you ask what’s been 
used, and it’s difficult to know because the 
creams look the same, they have names 
that are unfamiliar and, really, why would 
people remember unless they’ve logged it 
down?’ (GP17, FGD1)
Generally, this was described as a log 
completed by the parent, rather than the 
clinician. 
General information about eczema. 
Participants also wanted the eczema 
essentials (such as generic educational 
information about the nature and chronicity 
of eczema, the rationale for emollients and 
TCS, with instructions about how to apply 
topical treatments, and reassurance and 
guidance on TCS use) to allay parental fears. 
For TCS, healthcare professionals felt 
it important to explain the fingertip unit 
(a method of measuring TCS, where one 
fingertip covers an area the size of two 
palms):19 
‘The fingertip full thing’s quite good, I find. 
That’s what I quite often say to people, “a 
fingertip full for this crease”, and if that 
could be written down, then it’s clear.’ (GP8)
Parents, notably, also wanted non-
medical information on how to stop their 
child scratching, as this was often described 
as one of the most distressing behaviours 
related to eczema: 
‘J is constantly scratching, like, even in his 
sleep he does it. He obviously doesn’t know 
he’s doing it. It would be nice if there was a 
way to, like, stop him doing that.’ (P3)
Another suggestion was to include a 
reminder about re-ordering creams, as a 
delay in ordering repeat prescriptions was 
identified as a common problem. 
The format of the WAP. In terms of format, 
most parents wanted a paper copy of the 
WAP to display around the house. Others, 
‘in an ideal world’ (P7), would appreciate an 
electronic copy as well, which would facilitate 
sharing — such as e-mailing it to school — 
and retention, as a single paper copy is easily 
Box 2. Overview of WAP preferences
What should a WAP contain? 
• Individualised action steps for maintenance and flares
• When to seek medical advice
• Basic general information 
- Eczema pathogenesis
- Rationale for emollients and steroids
- Triggers and irritants
- Recognising flares and infection
• Record of treatment preferences
• Signposting to further information
What should a WAP look like?
• Ideally no more than one to two A4 pages
• Individualised actions on the front and general information on the back
• Visually appealing, with a balance of text and pictures
• Electronic and printed formats 
WAP format
• Needs to be easy to access/print/populate and, for GPs, ideally integrated into their clinical systems
WAP = written action plan.
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damaged or lost. GPs were focused on ease 
of access and speed of use. The prevailing 
opinion was that they wanted the tool to be 
embedded in their clinical system and pre-
populated as much as possible, for example, 
with patient details and treatments: 
‘If it could somehow be integrated into the 
software of the GP consultation … we have 
to make some notes in the records, so, if in 
some way when we’re saying to a patient 
“put the emollient on morning and the 
evening and the steroid on in the middle of 
the day”, or whatever, that typing in types 
into the form that you can just print off with 
the one click.’ (GP9) 
Once agreed and completed electronically, 
GPs envisaged it being saved in the medical 
records, and a printed copy given to the 
patient (and e-mailed if possible). 
The draft WAP had the individualised 
action steps on the front page, because 
parents wanted something they could 
refer to ‘on the fridge’ (P7), or ‘on a wall’ 
(P5). A traffic light colour coding system, 
to highlight the different steps, was also 
favoured: green for clear skin, amber for a 
flare, red for seek help. GPs cautioned that, 
as most surgeries do not currently have 
the resources to print in colour, the WAP 
needed to be usable in black and white as 
well. 
Figure 2. Page 1 of the final eczema written action 
plan (WAP) (© University of Bristol, 2017). For further 
information and to download a copy of the Eczema 
WAP, visit http://www.bristol.ac.uk/ewap.
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Finalising the WAP
The interviews identified a tension between 
having enough information to guide and 
support the parent, but not so much that it 
overwhelms or puts off the user. The first 
focus group felt the balance between these 
elements was not right in the authors’ draft 
WAP: 
‘I’m a bit overwhelmed in terms of the 
amount on the page, or the amount in each 
box. I don’t know why, but that’s my — I can 
see myself handing this to someone … and 
then it would have to take time to explain 
what it all means.’ (GP16, FGD1)
The authors modified the WAP to make it 
less detailed and, based on the suggestion 
of the focus group, moved video links to 
demonstrations of treatment application 
from the back ‘information page’ to the 
front ‘action page’. 
Subsequent participants felt that this 
invited users to look at them: 
‘I think they look central and they look 
important, simply because there’s not much 
other information. It makes you think that 
these videos will have important things.’ 
(GP17, FGD2)
This first focus group also helped to 
reconcile varying views on whether the 
WAP should be aimed at older children 
(between 7–12 years old) as well as parents. 
The group agreed that the authors should 
adopt a more pictorial approach, because 
pictures were seen as important, not only 
for engaging children, but also in terms of 
simplifying the action steps, and overcoming 
language and literacy barriers: 
‘I think images are sometimes more 
powerful … most people can, you know, this 
is the step and this is the arrow so you use 
this much, and then if it doesn’t improve, 
then you use — and you keep following the 
arrows until you get to where you want to 
be.’ (Pharmacist 1, FGD1). 
It was not possible to include a treatment 
log and keep the document to two sides of 
A4. GPs were sceptical that parents would 
have the time or inclination to complete it. 
This view also emerged in the second focus 
group. However, it was agreed that, although 
parents may not complete it at home, it 
may trigger conversations about treatment 
acceptability during eczema consultations: 
‘Within a couple of weeks you’re saying 
“oh my gosh, I can’t stand my child being 
so greased up, I’m stopping using the 
hydromol, it’s a right pain”, and maybe you 
don’t remember to write that down. But 
then, almost the next time you go back to 
the doctors, and you’re taking this with you, 
and … you’re only looking at the four things 
[four treatments written in the log in the 
WAP], and the doctor’s like, “well, do you 
want the repeat of those?” And you go “oh, 
hang on; we’ve stopped using that one ‘cos 
I hate it”.’ (P13, FGD2)
Because of its potential to promote the 
discussion and documentation of parents’ 
treatment preferences, the log was included 
in the final version. The final WAP, excluding 
the treatment log, is shown in Figure 2.
DISCUSSION
Summary
The management of eczema in children is 
often impeded by parents being confused 
about the treatment plan. They often felt 
that they had received insufficient advice 
and information from primary care. 
Healthcare professionals highlighted 
parental belief around eczema causation 
leading to differing treatment expectations. 
All participants noted problems around the 
documentation of treatment preferences.
A patient-held, written self-management 
plan that provides clear and simple 
individualised treatment guidance and 
educational information was seen as a 
means of overcoming these barriers. The 
authors developed an eczema WAP based 
on the views and preferences of parents 
and healthcare professionals. Consistent 
views about format and content enabled 
the authors to develop draft WAPs. Focus 
groups helped in finalising the WAP in 
relation to balancing the level of detail 
needed for effective self-care while 
ensuring users are not overwhelmed with 
information, deciding whether the target 
audience should include children as well 
as parents, and weighing up the value of 
including a log of treatments. 
The final, three-page eczema WAP 
comprises a stepped approach to treatment 
(maintenance, flare, seek help), eczema 
essentials (general information about 
eczema and its treatment), and a parent-
completed log of previous treatments and 
patient preferences. It favours brevity over 
detail and aims to minimise completion 
time for healthcare professionals. Pictures 
are used to engage children and aid 
communication and understanding.
Strengths and limitations
As far as the authors are aware, this is 
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the first qualitative study with a range of 
stakeholder perspectives investigating the 
potential value and desired content and 
format of a WAP on eczema. A breadth of 
viewpoints, drawing on interview and focus 
group data, has enabled the authors to 
develop a user-led WAP. Having clinical and 
non-clinical research team members aided 
reflexivity during discussions throughout 
data analysis. The unbalanced ratio of 
healthcare professionals to parents in 
the first focus group (4:1) may have been 
intimidating for the lone parent and could 
have resulted in a biased discussion. This 
was countered, however, by the facilitator, 
who ensured all voices were heard, and 
the balance (4:3) in the second group was 
more equal. The voices in this study are 
predominantly those of GPs and parents, 
rather than those of secondary care 
clinicians and stakeholders, with a focus on 
children with eczema aged <12 years. This 
reflects the authors’ decision to focus on 
this age group/disease of mild–moderate 
severity, because they both represent 
the majority of children managed in the 
primary care setting. The authors sought 
views from the other groups, primarily to 
check acceptability and content of a WAP 
from their viewpoint, but it is possible that 
they failed to identify relevant opinions from 
these other potential users. 
Comparison with existing literature
The difficulties in treating eczema in 
children highlighted by this research reflect 
the findings of work previously undertaken 
with parents and carers. This includes 
dissatisfaction with, and confusion about, 
treatment plans,8 and the desire to find a 
cure rather than just maintain control.20 
The authors also found the trial-and-error 
approach is hampered by parents’ struggle 
to recall names of treatments, and the lack 
of documentation about their treatment 
preferences in the medical notes.
National Institute for Health and Care 
Excellence guidance on eczema treatment 
highlights the importance of parental 
education to improve adherence and 
outcomes.1 These results support this but 
the findings suggest that, for any treatment 
plan to succeed, parental beliefs about the 
causes and management of eczema must 
be addressed, and the authors sought to 
achieve this by including key information 
about eczema in the WAP.
One of the difficulties the authors faced 
was how to include all of the content desired 
while still making it visually appealing and 
user friendly. A previous study looking at the 
readability and suitability of asthma WAPs 
exposed some of the common pitfalls: too 
many check boxes for medications and 
doses, lack of visual cues, such as boxes 
and arrows, practitioner-centred wording, 
and lack of white space.21 Some of these 
issues featured in an earlier draft of the 
authors’ WAP, but the readability and 
usability were evaluated by participants at 
each stage of its development, improving 
the final product. 
A qualitative systematic review looking 
at the design and use of WAPs in asthma 
and eczema depicted a preference for 
pictures for universal communication.22 A 
randomised trial also found a pictorial WAP 
was preferred by healthcare professionals, 
compared with a standard WAP, and 
provided clearer communication for self-
management and treatment.23 These 
findings also support the value of including 
pictures for engaging children and parents 
in managing eczema. 
Implications for research and practice
The authors have developed a WAP for 
children with eczema, using input from 
a wide range of parents, clinicians, and 
stakeholders. The draft WAP has been 
improved by a professional designer without 
changing the core aspects identified by 
the study participants. Further research 
is needed to trial the WAP in practice, to 
establish whether it can empower parents, 
children, and healthcare professionals to 
improve the management and treatment of 
childhood eczema in primary care.
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